Dexpramipexole could be a promising treatment for eosinophilic asthma
Oral doses of dexpramipexole lowered eosinophil counts by up to 80 percent and showed signs of improving lung function in a Phase II eosinophilic asthma trial.
List view / Grid view
Oral doses of dexpramipexole lowered eosinophil counts by up to 80 percent and showed signs of improving lung function in a Phase II eosinophilic asthma trial.
The investigational antibody evinacumab was able to lower triglycerides by up to 82 percent in severe hypertriglyceridemia patients with acute pancreatitis.
Using time of flight secondary ion mass spectrometry (ToF-SIMS) enabled the detection of nanoscale quantities of glycosaminoglycan (GAG) contaminants in heparin.
The FDA has published its finalised guidance for drug lifecycle management, including an improved framework for the management of post-approval changes.
The Phase III trial will evaluate the safety and efficacy of Pfizer’s PF-06939926 gene therapy in 99 paediatric Duchenne muscular dystrophy patients across 15 countries.
In a Phase II trial, a cannabidiol (CBD) sublingual tablet reduced pain scores in patients with diabetic peripheral neuropathy by approximately 50 percent.
In this article, Shannon Flynn outlines six of the key risks threatening pharmaceutical manufacturers’ recovery from COVID-19 in 2021.
Research shows the complexity and number of biologics is increasing, as is the frequency at which their active pharmaceutical ingredient (API) production is outsourced.
The new report shows over 8,000 planned inspections were postponed due to COVID-19 and outlines the FDA’s plan for a more consistent future state of operations.
The trial of DSP-0038, an Alzheimer’s disease psychosis drug designed using artificial intelligence, will assess its ability to improve the behavioural and psychological symptoms of dementia.
Organicell’s Zofin™ therapy has been approved by the Pakistani regulators to be used for a patient with severe COVID-19 on compassionate grounds.
In three Phase I/II trials an experimental gene therapy caused all but two patients with severe combined immunodeficiency to acquire and retain robust immune function for more than two years.
Three sessions of MDMA-assisted talk therapy resulted in significant symptom reductions for 88 percent of patients with severe, chronic post-traumatic stress disorder (PTSD).
The European Medicines Agency (EMA) has initiated a rolling reviews of Vero Cell, an inactivated COVID-19 vaccine, and sotrovimab, a monoclonal antibody.
In this podcast, Lonza’s Dr Deanna Mudie explains the importance of bioavailability, how to achieve desired bioavailability and top tips for how to select the correct dissolution media for your testing needs.